MovDisordV3, Main, Exploration, bibRecord, 004E25

A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease

Identifieur interne : 004E25 ( Main/Exploration ); précédent : 004E24; suivant : 004E26

A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease

Auteurs : William Ondo [États-Unis] ; Christine Hunter [États-Unis] ; Michael Almaguer [États-Unis] ; Joseph Jankovic [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1999-07.

RBID : ISTEX:CD9DB38087108E9001A5A123018F53781BE8A6E2

Descripteurs français

Pascal (Inist)
- Agoniste, Apomorphine, Chimiothérapie, Homme, Parkinson maladie, Récepteur dopaminergique, Traitement, Voie sublinguale.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Administration, Sublingual, Agonist, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Apomorphine, Apomorphine (administration & dosage), Apomorphine (therapeutic use), Chemotherapy, Disease Progression, Dopamine agonists, Dopamine receptor, Drug Administration Schedule, Female, Human, Humans, Male, Middle Aged, Parkinson Disease (classification), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Sublingual administration, Time Factors, Treatment, Treatment Outcome.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Apomorphine.
- chemical , therapeutic use : Antiparkinson Agents, Apomorphine.
- classification : Parkinson Disease.
- drug therapy : Parkinson Disease.
- Administration, Sublingual, Disease Progression, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Time Factors, Treatment Outcome.

Abstract

We tested a novel preparation of a sublingual apomorphine hydrochloride tablet (APO) in 10 patients with advanced Parkinson's disease complicated by motor fluctuations. After a dose titration, patients took either 40 mg APO three times per day alternating with levodopa doses (eight patients) or six doses of 20 mg APO taken concurrently with levodopa doses (two patients) for 3 months. Assessments included timed tapping and ambulation tests, Unified Parkinson's Disease Rating Scale (UPDRS), and patient diaries. Tapping speed while taking only APO (12 hours after stopping levodopa) was faster than while taking only levodopa (p <0.05). The daily levodopa dose decreased by 32.1% (p <0.01), yet the total “on” time increased from 73.5% ± 10.2% to 81.5% ± 7.5% of the day (p <0.01) after starting APO. “On” UPDRS part II scores (p <0.05) and “on” UPDRS part III (motor examination) scores (p <0.05) also improved. Adverse events such as nausea, orthostatic hypotension, and disagreeable taste did not limit the dose of APO in any case. The short‐term benefit and tolerability demonstrated in this study warrant further study of this new APO preparation.

Url:

https://api.istex.fr/document/CD9DB38087108E9001A5A123018F53781BE8A6E2/fulltext/pdf

DOI: 10.1002/1531-8257(199907)14:4<664::AID-MDS1017>3.0.CO;2-5

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease</title>
<author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name>
</author>
<author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
</author>
<author><name sortKey="Almaguer, Michael" sort="Almaguer, Michael" uniqKey="Almaguer M" first="Michael" last="Almaguer">Michael Almaguer</name>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation><country>États-Unis</country>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CD9DB38087108E9001A5A123018F53781BE8A6E2</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/1531-8257(199907)14:4<664::AID-MDS1017>3.0.CO;2-5</idno>
<idno type="url">https://api.istex.fr/document/CD9DB38087108E9001A5A123018F53781BE8A6E2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002948</idno>
<idno type="wicri:Area/Istex/Curation">002948</idno>
<idno type="wicri:Area/Istex/Checkpoint">003592</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Ondo W:a:novel:sublingual</idno>
<idno type="wicri:Area/Main/Merge">007B24</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:99-0386767</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002D87</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003A37</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002E80</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Ondo W:a:novel:sublingual</idno>
<idno type="wicri:Area/Main/Merge">007D29</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10435505</idno>
<idno type="wicri:Area/PubMed/Corpus">004163</idno>
<idno type="wicri:Area/PubMed/Curation">004163</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004285</idno>
<idno type="wicri:Area/Ncbi/Merge">000088</idno>
<idno type="wicri:Area/Ncbi/Curation">000088</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000088</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Ondo W:a:novel:sublingual</idno>
<idno type="wicri:Area/Main/Merge">007892</idno>
<idno type="wicri:Area/Main/Curation">004E25</idno>
<idno type="wicri:Area/Main/Exploration">004E25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease</title>
<author><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Almaguer, Michael" sort="Almaguer, Michael" uniqKey="Almaguer M" first="Michael" last="Almaguer">Michael Almaguer</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
<placeName><settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
<orgName type="university" n="3">Baylor College of Medicine</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-07">1999-07</date>
<biblScope unit="vol">14</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="664">664</biblScope>
<biblScope unit="page" to="668">668</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CD9DB38087108E9001A5A123018F53781BE8A6E2</idno>
<idno type="DOI">10.1002/1531-8257(199907)14:4<664::AID-MDS1017>3.0.CO;2-5</idno>
<idno type="ArticleID">MDS1017</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Sublingual</term>
<term>Agonist</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Apomorphine</term>
<term>Apomorphine (administration & dosage)</term>
<term>Apomorphine (therapeutic use)</term>
<term>Chemotherapy</term>
<term>Disease Progression</term>
<term>Dopamine agonists</term>
<term>Dopamine receptor</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (classification)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Sublingual administration</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Sublingual</term>
<term>Disease Progression</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Apomorphine</term>
<term>Chimiothérapie</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Récepteur dopaminergique</term>
<term>Traitement</term>
<term>Voie sublinguale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We tested a novel preparation of a sublingual apomorphine hydrochloride tablet (APO) in 10 patients with advanced Parkinson's disease complicated by motor fluctuations. After a dose titration, patients took either 40 mg APO three times per day alternating with levodopa doses (eight patients) or six doses of 20 mg APO taken concurrently with levodopa doses (two patients) for 3 months. Assessments included timed tapping and ambulation tests, Unified Parkinson's Disease Rating Scale (UPDRS), and patient diaries. Tapping speed while taking only APO (12 hours after stopping levodopa) was faster than while taking only levodopa (p <0.05). The daily levodopa dose decreased by 32.1% (p <0.01), yet the total “on” time increased from 73.5% ± 10.2% to 81.5% ± 7.5% of the day (p <0.01) after starting APO. “On” UPDRS part II scores (p <0.05) and “on” UPDRS part III (motor examination) scores (p <0.05) also improved. Adverse events such as nausea, orthostatic hypotension, and disagreeable taste did not limit the dose of APO in any case. The short‐term benefit and tolerability demonstrated in this study warrant further study of this new APO preparation.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
<settlement><li>Houston</li>
</settlement>
<orgName><li>Baylor College of Medicine</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Ondo, William" sort="Ondo, William" uniqKey="Ondo W" first="William" last="Ondo">William Ondo</name>
</region>
<name sortKey="Almaguer, Michael" sort="Almaguer, Michael" uniqKey="Almaguer M" first="Michael" last="Almaguer">Michael Almaguer</name>
<name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E25 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004E25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:CD9DB38087108E9001A5A123018F53781BE8A6E2
   |texte=   A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease

A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.